Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study

@inproceedings{Morjaria2017InhaledCU,
  title={Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study},
  author={Jaymin Bhagwanji Morjaria and Alan S Rigby and Alyn H. Morice},
  booktitle={Lung},
  year={2017}
}
Unlike many other COPD studies, the 4-year UPLIFT trial permitted inhaled corticosteroid (ICS) use during run-in and treatment phases. This provided the opportunity to prospectively observe the continuing effects of ICS on respiratory events in closely observed COPD population. We aimed to determine rate and number of episodes of pneumonia and exacerbations of COPD in patients entering the study on no ICS, fluticasone proprionate (FP), and other ICS. The UPLIFT dataset was examined… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
5 Citations
32 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…